• P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial
  • Seattle Genetics’ Investigational Therapy Fares Well in Multiple Myeloma Animal Models
  • Screening for Multiple Myeloma Precursor Could Cut Deaths from the Cancer, Study Finds
  • Selinexor Gains FDA Fast Track Designation for Refractory Multiple Myeloma Patients
  • China FDA Prepares to Review Evomela for Approval in Multiple Myeloma Treatment
  • Multiple Myeloma Research Foundation Awards $7 Million to Accelerate Precision Immunotherapies for Myeloma Patients
  • Xgeva Gains Europe’s Approval for Preventing Bone Lesions in Multiple Myeloma
  • Revlimid, Dexamethasone Combo Shows Benefits for Multiple Myeloma in Real-world Study
  • Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy
  • ACCoRd Trial to Test Ninlaro Treatment for  ASCT-Relapsed Multiple Myeloma
  • AbbVie, IMF Team Up to Study Gene Mutation in Myeloma Outcomes
  • SELLAS Vaccine More Than Doubles Time to Myeloma Progression, Phase 2 Trial Shows